Accessibility Menu
 
Phio Pharmaceuticals logo

Phio Pharmaceuticals

(NASDAQ) PHIO

Current Price$1.28
Market Cap$14.87M
Since IPO (2012)-100%
5 Year-100%
1 Year+6%
1 Month+27%

Phio Pharmaceuticals Financials at a Glance

Market Cap

$14.87M

Revenue (TTM)

$0.00

Net Income (TTM)

$8.70M

EPS (TTM)

$-1.50

P/E Ratio

-0.85

Dividend

$0.00

Beta (Volatility)

0.98 (Low)

Price

$1.28

Volume

2,791

Open

$1.26

Previous Close

$1.28

Daily Range

$1.26 - $1.30

52-Week Range

$0.81 - $4.19

PHIO News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Phio Pharmaceuticals

Industry

Biotechnology

Employees

6

CEO

Robert J. Bitterman, Sr., MBA

Headquarters

Marlborough, MA 01752, US

PHIO Financials

Key Financial Metrics (TTM)

Gross Margin

0%

Operating Margin

0%

Net Income Margin

0%

Return on Equity

-70%

Return on Capital

-44%

Return on Assets

-40%

Earnings Yield

-1.18%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$14.87M

Shares Outstanding

11.62M

Volume

2.79K

Short Interest

0.00%

Avg. Volume

3.78M

Financials (TTM)

Gross Profit

$3.00K

Operating Income

$9.22M

EBITDA

$9.22M

Operating Cash Flow

$7.98M

Capital Expenditure

$12.00K

Free Cash Flow

$7.99M

Cash & ST Invst.

$21.03M

Total Debt

$0.00

Phio Pharmaceuticals Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$0.00

N/A

Gross Profit

$1.00K

N/A

Gross Margin

0.00%

N/A

Market Cap

$14.87M

N/A

Market Cap/Employee

$2.97M

N/A

Employees

5

N/A

Net Income

$2.37M

-45.8%

EBITDA

$2.53M

-55.8%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Net Cash

$21.03M

+290.8%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

N/A

Return on Assets

-40.48%

N/A

Return on Invested Capital

-43.80%

N/A

Free Cash Flow

$2.08M

-51.5%

Operating Cash Flow

$2.08M

-51.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
MRKRMarker Therapeutics, Inc.
$1.32+0.76%
RNAZTransCode Therapeutics, Inc.
$8.60-1.04%
KPRXKiora Pharmaceuticals, Inc.
$1.94-0.51%
APVOAptevo Therapeutics Inc.
$4.17+0.97%

Trending Stocks

Symbol / CompanyPricePrice Chg
SKYQSky Quarry
$5.10+1.02%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$11.37-0.11%
INTCIntel
$50.38+0.05%
TQQQProShares Trust - ProShares UltraPro Qqq
$43.33+0.00%

Questions About PHIO

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.